April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Proteomic Profile of Plasma and Mucosal Samples from Patients with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
Author Affiliations & Notes
  • Christine M Mata
    Ophthalmology, Loyola University Medical Center, Maywood, IL
  • Julia Malalis
    Ophthalmology, Loyola University Medical Center, Maywood, IL
  • Daneyal Syed
    Pathology, Loyola University Medical Center, Maywood, IL
  • Daniel Kahn
    Pathology, Loyola University Medical Center, Maywood, IL
  • Michael Mosier
    Surgery, Loyola University Medical Center, Maywood, IL
  • Charles S Bouchard
    Ophthalmology, Loyola University Medical Center, Maywood, IL
  • Josephine Cunanan
    Pathology, Loyola University Medical Center, Maywood, IL
  • Debra Hoppensteadt
    Pathology, Loyola University Medical Center, Maywood, IL
  • Jawed Fareed
    Pathology, Loyola University Medical Center, Maywood, IL
  • Omer Iqbal
    Pathology, Loyola University Medical Center, Maywood, IL
  • Footnotes
    Commercial Relationships Christine Mata, None; Julia Malalis, None; Daneyal Syed, None; Daniel Kahn, None; Michael Mosier, None; Charles Bouchard, None; Josephine Cunanan, None; Debra Hoppensteadt, None; Jawed Fareed, None; Omer Iqbal, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 390. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Christine M Mata, Julia Malalis, Daneyal Syed, Daniel Kahn, Michael Mosier, Charles S Bouchard, Josephine Cunanan, Debra Hoppensteadt, Jawed Fareed, Omer Iqbal; Proteomic Profile of Plasma and Mucosal Samples from Patients with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Invest. Ophthalmol. Vis. Sci. 2014;55(13):390.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) are life-threatening, immune-complex hypersensitivity adverse drug reactions that affect the skin and mucous membranes, often resulting in significant ocular inflammation and systemic morbidity. The aim of this study was to compare the proteomic and coagulation profiles of sequential mucosal (ocular and oral) and plasma samples from patients with biopsy-confirmed SJS/TENS patients (5) and patients with non-SJS/TENS adverse drug reactions (ADR) (10).

Methods: Multiple plasma samples and swabs from ocular, oral, and skin lesions were obtained from patients with SJS/TEN (n=5). Samples from normal healthy controls were also obtained. The plasma was assayed for thrombin-antithrombin complex (TAT), prothrombin fragment F1.2, plasminogen activator inhibitor-1 (PAI-2), ZYMUPHEN platelet microparticle activity, HEMOCLOT protein C, and STACHROME antithrombin, using ELISA kits as per manufacturer’s instructions. The discharges were isolated following addition of 0.25 ml of saline to each swab and double centrifugation. The discharges and plasma samples were analyzed using SELDI-TOF technique.

Results: Analyses of the SJS/TEN plasma samples revealed a marked increase in the TAT complexes (6.3±5.9µg/ml), F1.2 (430.4±202.4 pmol/L), platelet microparticles (13.1±9.3nM) and protein C levels (90.5±63.4 %), with a corresponding decrease in PAI-1 (53.3±18.8ng/ml) and antithrombin levels (80.7±42.4 %) compared to normal healthy control plasma, suggesting a procoagulant state. Protein chip array of the SJS/TEN skin and oral mucosal samples exhibited two major peaks at 14.2 kDa and 15.6 kDa, in the same molecular weight range as recombinant human granulysin, a molecule implicated in the pathophysiology of SJS/TEN. Additional peaks at 11.7, 13.3 and 14.5 kDa were observed to be upregulated in SJS/TEN patients. These peaks were not present in the normal control group.

Conclusions: Procoagulant factors and unique peaks suggestive of granulysin may lead to the development of targeted therapy aimed to attenuate local and systemic inflammatory processes in patients with SJS/TEN.

Keywords: 663 proteomics  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×